|Bid||20.00 x 800|
|Ask||27.19 x 800|
|Day's range||24.91 - 25.87|
|52-week range||18.16 - 36.48|
|Beta (5Y monthly)||2.25|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||36.78|
Good afternoon and welcome to MacroGenics' conference call to discuss our second-quarter 2021 financial and operational results. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change, except to the extent required by applicable law.
What happened Shares of MacroGenics (NASDAQ: MGNX) had tumbled 4.8% lower at 11:27 a.m. EDT on Friday. The decline came after the company provided its second-quarter update. MacroGenics reported revenue of $30.
MacroGenics (MGNX) delivered earnings and revenue surprises of -135.71% and -13.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?